• 1. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Catalysts and Inorganic Chemicals Inorganic Compounds Homogeneous non-metal compounds Homogeneous other non-metal compounds

Introduction to 5-Chloro-6-isopropyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (CAS No: 1203898-28-5)

5-Chloro-6-isopropyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile is a significant compound in the realm of pharmaceutical chemistry, characterized by its unique structural and functional attributes. This compound, identified by the CAS number 1203898-28-5, has garnered attention due to its potential applications in the synthesis of bioactive molecules. The presence of a chloro group, an isopropyl substituent, and a cyano functional group on the pyridine ring imparts distinct reactivity, making it a valuable intermediate in drug discovery and development.

The molecular structure of 5-Chloro-6-isopropyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (CAS No: 1203898-28-5) exhibits a framework that is conducive to further chemical modifications. The pyridine core, a common motif in many pharmacologically active compounds, serves as a scaffold for diverse functionalization. This structural feature allows for the exploration of various derivatives that could exhibit enhanced biological activity. The chloro group, in particular, is known to participate in nucleophilic substitution reactions, enabling the introduction of different functional moieties at specific positions on the ring.

In recent years, there has been growing interest in the development of novel heterocyclic compounds for their therapeutic potential. 5-Chloro-6-isopropyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (CAS No: 1203898-28-5) fits well within this trend, as it can be further modified to produce molecules with targeted pharmacological effects. For instance, researchers have been exploring its utility in the synthesis of kinase inhibitors, which are crucial in treating cancers and inflammatory diseases. The cyano group on the pyridine ring can be transformed into other functionalities such as amides or carboxylic acids, expanding its synthetic versatility.

One of the most compelling aspects of 5-Chloro-6-isopropyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (CAS No: 1203898-28-5) is its role in the development of antimicrobial agents. The structural features of this compound make it a promising candidate for designing molecules that can disrupt bacterial cell walls or inhibit essential metabolic pathways. Recent studies have highlighted its potential in combating resistant strains of bacteria by targeting unique enzymatic pathways that are less likely to be affected by existing antibiotics. This aligns with the global effort to address the growing challenge of antibiotic resistance.

The synthesis of 5-Chloro-6-isopropyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (CAS No: 1203898-28-5) involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include condensation reactions followed by chlorination and alkylation steps. Advanced techniques such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions have also been employed to enhance the efficiency of these processes. The availability of high-quality starting materials and well-defined reaction conditions are critical factors that contribute to the successful synthesis of this compound.

The pharmacological evaluation of derivatives derived from 5-Chloro-6-isopropyl-2-oxyo1,2-dihydro3-pyridinecarbonitrile (CAS No: 1203898 28 5) has revealed several interesting findings. In vitro studies have demonstrated its ability to inhibit certain enzymes involved in cancer cell proliferation. Additionally, preclinical trials have shown promising results in animal models for treating inflammatory disorders. These findings underscore the importance of this compound as a lead molecule for further drug development. The ability to fine-tune its structure through medicinal chemistry approaches offers a pathway to develop more effective and selective therapeutic agents.

The future prospects for 5-Chloro 6isopropyl 2 oxolo1 2 dihydro3 pyridinecarbonitrile (CAS No: 1203898 28 5) are bright, given its versatile structural framework and potential applications across multiple therapeutic areas. As research continues to uncover new biological targets and mechanisms, this compound is likely to play a pivotal role in developing next-generation pharmaceuticals. Collaborative efforts between academic researchers and industry scientists will be essential in translating these findings into clinical reality. The continued exploration of its derivatives will undoubtedly lead to innovative solutions for some of today's most pressing medical challenges.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)